Thrombopoietin-receptor agonists in haematological disorders: The Danish experience

Platelets

Volumn 23, Issue 6, 2012, Pages 423-429

  Gudbrandsdottir, Sif ^a,c   Frederiksen, Henrik ^b   Hasselbalch, Hans ^a  

^a Mental Health Center Glostrup   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Eltrombopag; Off label use; Primary immune thrombocytopenia; Romiplostim; Secondary thrombocytopenia

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; DANAZOL; DEXAMETHASONE; ELTROMBOPAG; IMMUNOGLOBULIN; PREDNISOLONE; RITUXIMAB; ROMIPLOSTIM; THROMBOPOIETIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; CELIAC DISEASE; CHEMICALLY INDUCED THROMBOCYTOPENIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG MONITORING; FATIGUE; FEMALE; HEADACHE; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HEREDITARY SPHEROCYTOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LUNG EMBOLISM; MALE; MEDICAL RECORD REVIEW; MYELODYSPLASTIC SYNDROME; NAUSEA; OFF LABEL DRUG USE; PRIORITY JOURNAL; SPLENECTOMY; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, HEMOLYTIC, AUTOIMMUNE; BENZOATES; BLOOD PLATELETS; CELIAC DISEASE; DENMARK; FEMALE; HIV INFECTIONS; HUMANS; HYDRAZINES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OFF-LABEL USE; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; RECURRENCE; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 84864838019     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2011.634931     Document Type: Article

References (24)

1. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-186.
2. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009;113:2386-2393.
3. Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 2006;133:364-374.
4. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999;94:909-913.
5. Solberg Jr LA. Biologic aspects of thrombopoietins and the development of therapeutic agents. Curr Hematol Rep 2005;4:423-428.
6. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-2247.
7. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet 2008;371:395-403.
8. Frampton JE, Lyseng-Williamson KA. Romiplostim. Drugs 2009;69:307-317.
9. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebocontrolled trial. Lancet 2009;373:641-648.
10. Garnock-Jones KP, Keam SJ. Eltrombopag. Drugs 2009; 69:567-576.
11. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113:2161-2171.
12. Saleh MN, Cheng G, Bussel JB, Sun H, Mayer B, Bailey CK, Brainsky A. EXTEND Study update: safety and efficacy of eltrombopag in adults with chronic immune thrombocytopenia (ITP) from June 2006 to February 2010. Blood 2010;116:Suppl:36-36.
13. Olen O, Montgomery SM, Elinder G, Ekbom A, Ludvigsson JF. Increased risk of immune thrombocytopenic purpura among inpatients with celiac disease. Scand J Gastroenterol 2008;43:416-422.
14. Altintas A, Pasa S, Cil T, Bayan K, Gokalp D, Ayyildiz O. Thyroid and celiac diseases autoantibodies in patients with adult chronic idiopathic thrombocytopenic purpura. Platelets 2008;19:252-257.
15. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227-2236.
16. Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010;28:437-444.
17. Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer 2011;117:992-1000.
18. Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin JL, Berger DP. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010;116: 3163-3170.
19. Kellum A, Jagiello-Gruszfeld A, Bondarenko IN, Patwardhan R, Messam C, Mostafa KY. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Curr Med Res Opin 2010;26:2339-2346.
20. Koehrer S, Keating MJ, Wierda WG. Eltrombopag, a secondgeneration thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. Leukemia 2010;24: 1096-1098.
21. Beck JC, Burke MJ, Tolar J. Response of refractory immune thrombocytopenia after bone marrow transplantation to romiplostim. Pediatr Blood Cancer 2010;54:490-491.
22. Pecci A, Gresele P, Klersy C, Savoia A, Noris P, Fierro T, Bozzi V, Mezzasoma AM, Melazzini F, Balduini CL. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood 2010;116: 5832-5837.
23. http://www.nplatehcp.com/safety-information.html
24. Gupta R, Soupir CP, Johari V, Hasserjian RP. Myelodysplastic syndrome with isolated deletion of chromosome 20q: An indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol 2007;139:265-268.